Filing Summary
Registrant: Flora Growth Corp., not Zerostack Corp. as stated in the request metadata. The Form 8-K was filed December 6, 2023, regarding events occurring November 30, 2023.
Business Context and Reporting Period
The filing reports the resignation of director Thomas Solomon effective November 30, 2023, and the resulting loss of compliance with Nasdaq’s audit committee composition requirements. It is not a periodic financial report and does not provide operating results for a reporting period.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material Changes
- Thomas Solomon resigned as a director on November 30, 2023.
- The filing states that his resignation was not due to any disagreement with the company regarding its operations, policies, or practices.
- Following his resignation, the audit committee no longer had the three independent members required by Nasdaq Listing Rule 5605(c)(2)(A).
- Flora Growth notified Nasdaq on December 4, 2023, and received Nasdaq’s noncompliance notification on December 6, 2023.
Outlook, Risks, and Contingencies
Nasdaq granted the company a cure period to regain compliance. The deadline is the earlier of the next annual shareholders’ meeting or November 30, 2024. If the next annual meeting occurs before May 28, 2024, the company must demonstrate compliance by May 28, 2024. Failure to regain compliance could create continued listing risk, although the filing does not state that delisting proceedings have commenced.
Key Facts to Verify
- Confirm that the intended registrant is Flora Growth Corp. and not Zerostack Corp.
- Verify the appointment or election of sufficient independent directors to restore audit committee compliance.
- Confirm the date of the next annual shareholders’ meeting and the applicable cure deadline.
- Review subsequent SEC filings for Nasdaq compliance updates or any listing-status developments.